BeOne Medicines to Present at Morgan Stanley Global Healthcare Conference

BeOne Medicines will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, with a fireside chat at 1:50 p.m. EDT. The live webcast can be accessed from the investors section of the Company's website. BeOne is a global oncology company with a portfolio spanning hematology and solid tumors, and is committed to improving access to medicines for cancer patients worldwide.

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025. The company will present a fireside chat at 1:50 p.m. EDT. The live webcast of this event can be accessed from the investors section of the Company’s website at [BeOne Medicines Investor Relations](https://ir.beonemedicines.com), [BeOne Medicines HKEX Investor Relations](https://hkexir.beonemedicines.com), and [BeOne Medicines SSE Investor Relations](https://sseir.beonemedicines.com). An archived webcast will also be available on the Company’s website.

BeOne Medicines is a global oncology company domiciled in Switzerland, focusing on discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting the development of its diverse pipeline of novel therapeutics through internal capabilities and collaborations. The company has a growing global team of over 11,000 colleagues across six continents, committed to improving access to medicines for more patients who need them.

In a recent development, BeOne Medicines has agreed to sell its royalty rights on Amgen's cancer drug Imdelltra for up to $950 million to Royalty Pharma. The upfront payment is $885 million, with the option to sell remaining royalties for up to $65 million. BeOne will share in a portion of the royalty on annual sales above $1.5 billion and maintain rights to other assets under the existing collaboration with Amgen. Imdelltra, a first-in-class immunotherapy, is approved in the US for patients with extensive-stage small cell lung cancer (ES-SCLC).

This transaction provides BeOne with immediate cash to advance its internal pipeline while reducing risks from potential Imdelltra competition. The deal also reflects the growing interest in DLL3-targeting therapies, with several large companies exploring the space. Imdelltra's sales reached $215 million in the first half of 2025, and analysts' consensus currently pegs the drug could reach $2.8 billion in sales by 2035.

References:
[1] https://www.marketscreener.com/news/beone-to-present-at-the-morgan-stanley-23rd-annual-global-healthcare-conference-ce7c50d9d98cfe27
[2] https://www.ainvest.com/news/beone-medicines-cashes-amgen-cancer-drug-royalties-950mln-pharma-tie-2508/